← boardnext 2026-08-01next 2027-04-14next 2028-11next 2029-04next 2038-05
BMRN
BioMarin Pharmaceuticaldistress 1/10 · well-funded / low risk$57.89-1%today-10% from 52w high
Lead: Achondroplasia
Revenue
$766M
Liquidity
$2222M
Runway
—
Shares 1y
+1%
Price & events
+1.2% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
-3.5%
1W
+2.5%
1M
+7.2%
3M
+3.0%
6M
-3.0%
1Y
-31.4%
2Y
-24.9%
5Y
-32.9%
All
Overview
- Market Cap
- $11.19B
- Enterprise Value
- $10.40B
- Volume
- 36.64K
- 52 Week Range
- $49.67 – $64.08
- Total Shares
- 193.28M
- Float Shares
- 192.09M
- Short %
- 7.22%
- % Held by Insiders
- 0.35%
- % Held by Institutions
- 102.13%
- RVOL
- 0.02x
- Beta
- 0.24
Pipeline stages · 5 programs
Vosoritide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BMN 351
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Valoctocogene roxaparvovec
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 14 trials · 14 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08-01 Estimated 50% readout ~2026-10-15 | Phase 3 | Vosoritide | Hypochondroplasia | — | active not recruiting |
| 2027-03 Estimated 50% readout ~2027-04-15 | Phase 2 | Vosoritide Injection | Noonan Syndrome | — | recruiting |
| 2027-04-14 Estimated 50% readout ~2027-05-29 | Phase 1/2 | BMN 351 | Duchenne Muscular Dystrophy | — | active not recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | BMN 111 | Achondroplasia | — | active not recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 1/2 | BMN 307 | Phenylketonuria (PKU) | — | active not recruiting |
Show all 14 trials · 9 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | vosoritide | Achondroplasia | — | active not recruiting |
| 2028-06-30 Estimated 50% readout ~2028-08-14 | Phase 2 | Vosoritide | Hypochondroplasia | — | recruiting |
| 2028-11 Estimated 50% readout ~2028-12-16 | Phase 1/2 | Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331 | Hereditary Angioedema, HAE | — | active not recruiting |
| 2029-04 Estimated 50% readout ~2029-05-16 | Phase 1/2 | Valoctocogene roxaparvovec | Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII | — | active not recruiting |
| 2029-06 Estimated 50% readout ~2029-08-15 | Phase 2/3 | BMN 333, Vosoritide Injection [Voxzogo] | Achondroplasia | — | recruiting |
| 2031-06 Estimated 50% readout ~2031-08-15 | Phase 3 | BMN 111 | Achondroplasia | — | active not recruiting |
| 2031-12 Estimated 50% readout ~2032-01-15 | Phase 2 | BMN 351 | Duchenne Muscular Dystrophy (DMD) | — | enrolling by invitation |
| 2038-05 Estimated 50% readout ~2038-06-15 | Phase 2 | Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band | Achondroplasia | — | active not recruiting |
| 2040-12 Estimated 50% readout ~2041-02-14 | Phase 3 | Vosoritide | Hypochondroplasia | — | enrolling by invitation |
Catalyst news & presentations · 7
- 2026-08-03Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-04-27partnershipcompleted merger with Amicus TherapeuticsSEC 8-K
- 2026-03-16trial discontinuedVOXZOGO · Discontinued Phase 2 trials in Turner syndrome, SHOX-deficiency, and ACAN-deficiency due to slipped capital femoral epiphysis events.SEC 8-K
- on or about February 12, 2026filing acceptanceFiled (NDA/BLA)Closing of private offering of $850M senior notesSEC 8-K
- 2025-12-19trial discontinuedBMN 349 · BioMarin announced discontinuation of BMN 349 for AATD-associated liver disease.SEC 8-K
- 2025-12-19partnershipBioMarin enters into agreement to acquire Amicus for $14.50 per share cash.SEC 8-K
- 2025-05-16partnershipBioMarin and Inozyme enter into merger agreement; tender offer at $4.00 per share.SEC 8-K
Approved drugs (8)
- VOXZOGOVOSORITIDE2021 · Prescription
- PALYNZIQPEGVALIASE-PQPZ2018 · Prescription
- BRINEURACERLIPONASE ALFA2017 · Prescription
- VIMIZIMELOSULFASE ALFA2014 · Prescription
- KUVANSAPROPTERIN DIHYDROCHLORIDE2013 · Prescription
- KUVANSAPROPTERIN DIHYDROCHLORIDE2007 · Prescription
- NAGLAZYMEGALSULFASE2005 · Prescription
- ALDURAZYMELARONIDASE2003 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $88 (+52% upside) · 25 analysts
- 2026-07-16CitigroupBuy
- 2026-07-07RBC CapitalSector Perform
- 2026-05-22Canaccord GenuityBuy
- 2026-05-19B of A SecuritiesBuy
- 2026-05-19CitigroupBuy
- 2026-05-18HC Wainwright & Co.Neutral
Competitors — Achondroplasia
Recent news
- 2026-07-22BioMarin: Commercial Infrastructure Is The Hidden Growth Asset - Seeking Alpha
- 2026-07-21Biomarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21BioMarin stock trades steady as rare disease revenue grows and gene therapy outlook develops - Ad-hoc-news.de
- 2026-07-17How FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Story - simplywall.st
- 2026-07-17How FDA Review of VOXZOGO Full-Approval Data at BioMarin (BMRN) Has Changed Its Investment Story - simplywall.st
- 2026-07-172 Reasons to Avoid BMRN and 1 Stock to Buy Instead - Yahoo Finance
- 2026-07-172 Reasons to Avoid BMRN and 1 Stock to Buy Instead - StockStory
- 2026-07-17BioMarin (BMRN) Wins FDA Review For VOXZOGO Full Approval In Achondroplasia - Sahm
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.